

May 3rd, 2019

STATICH: May newsletter

Dear STATICH collaborators,

Trial status

A total of **16 participants** are now enrolled: 11 in the Anticoagulant part of the study (patients with atrial fibrillation) and 5 in the Antiplatelet part (patients with vascular disease).

International collaboration

Several other on-going or planned trials in Europe and North America are assessing effects of antithrombotic treatment after ICH (country of origin):

Trials of antiplatelet agents:

- RESTART (UK) (results will be presented at ESOC)
- RESTART Nord de France

Trials of anticoagulant agents:

- SoSTART (UK)
- A3ICH (France)
- APACHE-AF (The Netherlands)
- ASPIRE (USA)
- NASPAF-ICH/ENRICH-AF (Canada)
- PRESTIGE-AF (Germany)

In addition, the STROKECLOSE trial of left atrial appendage occlusion is on-going (Sweden).

When the results of STATICH have been completed, data from the trial will be combined with data from the other trials in a patient-level meta-analysis. This will greatly increase the value of STATICH.

Reminder: Collaborators' meeting during ESOC in Milan

Time: Thursday May 23rd at 14.30-15.30

Place: Meeting Room Suite 3, level 2 in the MiCo Congress Centre

Agenda:

1. Short presentation of background and design
2. Trial status
3. RESTART results: Any implications for STATICH?

Light refreshments will be served. If you haven't done so already, please reply to k.t.larsen@medisin.uio.no if you will join. We are looking forward to seeing you there!

Collaborators' meeting during the Nordic Stroke Congress 2019 in Tromsø in August

We would also like to invite all collaborators to a meeting during the Nordic Stroke Congress in Tromsø, during the lunch break on Thursday August 22nd. More detailed information will come nearer the time. We hope to see many of you there as well!

Best wishes,

Kristin T.Larsen
Oslo

Johanna Pennlert
Umeå

Eva-Lotta Glader
Umeå

Christina Kruuse
Copenhagen

Eivind Berge
Oslo